Third Quarter 2024 Summary & Recent Business Highlights:
- Total revenue increased 5% year-over-year to
$73.1 million - Lymphedema product revenue increased 4% over Q3 2023
- Airway clearance product revenue increased 10% over Q3 2023
- Net income of
$5.2 million versus$22.3 million in Q3 2023 - Adjusted EBITDA of
$10.7 million versus$7.7 million in Q3 2023 - Operating cashflow of
$24.3 million year-to-date, compared to$17.5 million in the prior year period - Ended Q3 2024 with
$82.1 million in cash and cash equivalents - Launched Nimbl, our next-generation lymphedema therapy platform for upper extremity conditions
- Announced publication of positive clinical trial results in
VA lymphedema patients using Flexitouch therapy - Authorized a program to repurchase up to
$30.0 million of the Company’s common stock
“In the third quarter, we delivered solid gross margin expansion, drove continued improvements in profitability, and achieved double-digit growth in both our commercial and
Share Repurchase Program
The Company also announced today that the Board of Directors of the Company authorized a program to repurchase up to
Third Quarter 2024 Financial Results
Total revenue in the third quarter of 2024 increased
Gross profit in the third quarter of 2024 increased
Operating expenses in the third quarter of 2024 increased
Operating income was
Other income was
Income tax expense was
Net income in the third quarter of 2024 was
Weighted average shares used to compute diluted net income per share were 24.3 million and 23.8 million for the third quarters of 2024 and 2023, respectively.
Adjusted EBITDA was
First Nine Months 2024 Financial Results
Total revenue for the nine months ended
Net income for the nine months ended
Weighted average shares used to compute diluted net income per share were 24.1 million and 23.0 million for the nine months ended
Adjusted EBITDA was
Balance Sheet Summary
As of
2024 Financial Outlook
The Company is updating its 2024 financial outlook and now expects full year 2024 total revenue in the range of
Conference Call
Management will host a conference call with a question-and-answer session at
For those unable to participate, a replay of the call will be available for two weeks at 877-660-6853 (201-612-7415 for international callers); access code 13748661. The webcast will be archived at investors.tactilemedical.com.
About
Legal Notice Regarding Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “continue,” “confident,” “outlook,” “guidance,” “project,” “goals,” “look forward,” “poised,” “designed,” “plan,” “return,” “focused,” “prospects” or “remain” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the Company’s control that can make such statements untrue, including, but not limited to, the Company’s ability to obtain reimbursement from third-party payers for its products; the impacts of inflation, rising interest rates or a recession; the adequacy of the Company’s liquidity to pursue its business objectives; adverse economic conditions or intense competition; price increases for supplies and components; wage and component price inflation; loss of a key supplier; entry of new competitors and products; compliance with and changes in federal, state and local government regulation; loss or retirement of key executives, including transition matters related to the Company’s recent Chief Executive Officer change; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; the effects of current and future
Use of Non-GAAP Financial Measures
This press release includes the non-GAAP financial measures of Adjusted EBITDA, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, and non-GAAP net income, which differ from financial measures calculated in accordance with
Adjusted EBITDA in this release represents net income or loss, plus interest expense, net, or less interest income, net, less income tax benefit or plus income tax expense, plus depreciation and amortization, plus stock-based compensation expense, plus or minus the change in fair value of earn-out and plus executive transition costs. Non-GAAP gross profit in this release represents gross profit plus non-cash intangible asset amortization expense. Non-GAAP gross margin in this release represents non-GAAP gross profit divided by revenue. Non-GAAP operating income in this release represents operating income adjusted for non-cash intangible asset amortization expense, change in fair value of earn-out and executive transition expenses. Non-GAAP net income represents net income adjusted for non-cash intangible asset amortization expense, change in fair value of earn-out and executive transition expenses, and adjusted for the income tax effect on reconciling items. Reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in this press release.
These non-GAAP financial measures are presented because the Company believes they are useful indicators of its operating performance. Management uses these measures principally as measures of the Company’s operating performance and for planning purposes, including the preparation of the Company’s annual operating plan and financial projections. The Company believes these measures are useful to investors as supplemental information and because they are frequently used by analysts, investors and other interested parties to evaluate companies in its industry. The Company also believes these non-GAAP financial measures are useful to its management and investors as a measure of comparative operating performance from period to period. In addition, Adjusted EBITDA is used as a performance metric in the Company’s compensation program.
The non-GAAP financial measures presented in this release should not be considered as an alternative to, or superior to, their respective GAAP financial measures, as measures of financial performance or cash flows from operations as a measure of liquidity, or any other performance measure derived in accordance with GAAP, and they should not be construed to imply that the Company’s future results will be unaffected by unusual or non-recurring items. In addition, Adjusted EBITDA is not intended to be a measure of free cash flow for management’s discretionary use, as it does not reflect certain cash requirements such as tax payments, debt service requirements, capital expenditures and certain other cash costs that may recur in the future. Adjusted EBITDA contains certain other limitations, including the failure to reflect our cash expenditures, cash requirements for working capital needs and cash costs to replace assets being depreciated and amortized. In evaluating non-GAAP financial measures, you should be aware that in the future the Company may incur expenses that are the same as or similar to some of the adjustments in this presentation. The Company’s presentation of non-GAAP financial measures should not be construed to imply that its future results will be unaffected by any such adjustments. Management compensates for these limitations by primarily relying on the Company’s GAAP results in addition to using non-GAAP financial measures on a supplemental basis. The Company’s definition of these non-GAAP financial measures is not necessarily comparable to other similarly titled captions of other companies due to different methods of calculation.
| Condensed Consolidated Balance Sheets | ||||||||
| (Unaudited) | ||||||||
| (In thousands, except share and per share data) | 2024 | 2023 | ||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 82,146 | $ | 61,033 | ||||
| Accounts receivable | 39,970 | 43,173 | ||||||
| Net investment in leases | 13,953 | 14,195 | ||||||
| Inventories | 21,176 | 22,527 | ||||||
| Prepaid expenses and other current assets | 5,127 | 4,366 | ||||||
| Total current assets | 162,372 | 145,294 | ||||||
| Non-current assets | ||||||||
| Property and equipment, net | 5,878 | 6,195 | ||||||
| Right of use operating lease assets | 17,553 | 19,128 | ||||||
| Intangible assets, net | 43,708 | 46,724 | ||||||
| 31,063 | 31,063 | |||||||
| Accounts receivable, non-current | 3,628 | 10,936 | ||||||
| Deferred income taxes | 19,719 | 19,378 | ||||||
| Other non-current assets | 3,803 | 2,720 | ||||||
| Total non-current assets | 125,352 | 136,144 | ||||||
| Total assets | $ | 287,724 | $ | 281,438 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 7,290 | $ | 6,659 | ||||
| Note payable | 2,956 | 2,956 | ||||||
| Accrued payroll and related taxes | 13,086 | 16,789 | ||||||
| Accrued expenses | 7,088 | 5,904 | ||||||
| Income taxes payable | 611 | 1,467 | ||||||
| Operating lease liabilities | 2,883 | 2,807 | ||||||
| Other current liabilities | 3,240 | 4,475 | ||||||
| Total current liabilities | 37,154 | 41,057 | ||||||
| Non-current liabilities | ||||||||
| Note payable, non-current | 23,959 | 26,176 | ||||||
| Accrued warranty reserve, non-current | 1,448 | 1,681 | ||||||
| Income taxes payable, non-current | 495 | 446 | ||||||
| Operating lease liabilities, non-current | 16,767 | 18,436 | ||||||
| Total non-current liabilities | 42,669 | 46,739 | ||||||
| Total liabilities | 79,823 | 87,796 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, |
— | — | ||||||
| Common stock, |
24 | 24 | ||||||
| Additional paid-in capital | 181,739 | 174,724 | ||||||
| Retained earnings | 26,138 | 18,894 | ||||||
| Total stockholders’ equity | 207,901 | 193,642 | ||||||
| Total liabilities and stockholders’ equity | $ | 287,724 | $ | 281,438 | ||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| (In thousands, except share and per share data) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue | ||||||||||||||||
| Sales revenue | $ | 63,168 | $ | 58,866 | $ | 180,742 | $ | 171,459 | ||||||||
| Rental revenue | 9,925 | 10,720 | 26,657 | 25,312 | ||||||||||||
| Total revenue | 73,093 | 69,586 | 207,399 | 196,771 | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Cost of sales revenue | 15,603 | 17,016 | 46,810 | 48,523 | ||||||||||||
| Cost of rental revenue | 2,703 | 3,211 | 8,270 | 9,122 | ||||||||||||
| Total cost of revenue | 18,306 | 20,227 | 55,080 | 57,645 | ||||||||||||
| Gross profit | ||||||||||||||||
| Gross profit - sales revenue | 47,565 | 41,850 | 133,932 | 122,936 | ||||||||||||
| Gross profit - rental revenue | 7,222 | 7,509 | 18,387 | 16,190 | ||||||||||||
| Gross profit | 54,787 | 49,359 | 152,319 | 139,126 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Sales and marketing | 26,838 | 26,030 | 82,803 | 80,538 | ||||||||||||
| Research and development | 2,417 | 1,964 | 6,794 | 6,030 | ||||||||||||
| Reimbursement, general and administrative | 18,118 | 16,449 | 51,158 | 46,874 | ||||||||||||
| Intangible asset amortization and earn-out | 633 | (3,073 | ) | 1,898 | (557 | ) | ||||||||||
| Total operating expenses | 48,006 | 41,370 | 142,653 | 132,885 | ||||||||||||
| Income from operations | 6,781 | 7,989 | 9,666 | 6,241 | ||||||||||||
| Other income (expense) | 452 | (404 | ) | 832 | (2,235 | ) | ||||||||||
| Income before income taxes | 7,233 | 7,585 | 10,498 | 4,006 | ||||||||||||
| Income tax expense (benefit) | 2,078 | (14,714 | ) | 3,254 | (16,307 | ) | ||||||||||
| Net income | $ | 5,155 | $ | 22,299 | $ | 7,244 | $ | 20,313 | ||||||||
| Net income per common share | ||||||||||||||||
| Basic | $ | 0.21 | $ | 0.95 | $ | 0.30 | $ | 0.89 | ||||||||
| Diluted | $ | 0.21 | $ | 0.94 | $ | 0.30 | $ | 0.88 | ||||||||
| Weighted-average common shares used to compute net income per common share | ||||||||||||||||
| Basic | 23,985,364 | 23,483,269 | 23,842,049 | 22,714,574 | ||||||||||||
| Diluted | 24,254,176 | 23,848,729 | 24,070,084 | 22,987,667 | ||||||||||||
| Condensed Consolidated Statements of Cash Flows | ||||||||
| (Unaudited) | ||||||||
| Nine Months Ended |
||||||||
| (In thousands) | 2024 | 2023 | ||||||
| Cash flows from operating activities | ||||||||
| Net income | $ | 7,244 | $ | 20,313 | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 5,079 | 4,916 | ||||||
| Deferred income taxes | (341 | ) | (20,717 | ) | ||||
| Stock-based compensation expense | 5,969 | 5,597 | ||||||
| Loss on disposal of property and equipment and intangibles | 308 | 3 | ||||||
| Change in fair value of earn-out liability | — | (2,475 | ) | |||||
| Changes in assets and liabilities, net of acquisition: | ||||||||
| Accounts receivable | 3,203 | 10,947 | ||||||
| Net investment in leases | 242 | 2,527 | ||||||
| Inventories | 1,351 | (374 | ) | |||||
| Income taxes | (807 | ) | (99 | ) | ||||
| Prepaid expenses and other assets | (1,844 | ) | (369 | ) | ||||
| Right of use operating lease assets | (18 | ) | 292 | |||||
| Accounts receivable, non-current | 7,308 | 8,425 | ||||||
| Accounts payable | 582 | (3,622 | ) | |||||
| Accrued payroll and related taxes | (3,703 | ) | (2,316 | ) | ||||
| Accrued expenses and other liabilities | (251 | ) | (5,545 | ) | ||||
| Net cash provided by operating activities | 24,322 | 17,503 | ||||||
| Cash flows from investing activities | ||||||||
| Purchases of property and equipment | (1,932 | ) | (1,424 | ) | ||||
| Proceeds from sale of property and equipment | 12 | — | ||||||
| Intangible assets expenditures | (85 | ) | (117 | ) | ||||
| Net cash used in investing activities | (2,005 | ) | (1,541 | ) | ||||
| Cash flows from financing activities | ||||||||
| Proceeds from issuance of note payable | — | 8,250 | ||||||
| Payments on earn-out | — | (5,000 | ) | |||||
| Payments on note payable | (2,250 | ) | (2,250 | ) | ||||
| Payments on revolving line of credit | — | (8,250 | ) | |||||
| Payments of deferred debt issuance costs | — | (125 | ) | |||||
| Proceeds from exercise of common stock options | 2 | 13 | ||||||
| Proceeds from the issuance of common stock from the employee stock purchase plan | 1,044 | 882 | ||||||
| Proceeds from issuance of common stock at market | — | 34,625 | ||||||
| Net cash (used in) provided by financing activities | (1,204 | ) | 28,145 | |||||
| Net increase in cash and cash equivalents | 21,113 | 44,107 | ||||||
| Cash and cash equivalents – beginning of period | 61,033 | 21,929 | ||||||
| Cash and cash equivalents – end of period | $ | 82,146 | $ | 66,036 | ||||
| Supplemental cash flow disclosure | ||||||||
| Cash paid for interest | $ | 1,612 | $ | 2,810 | ||||
| Cash paid for taxes | $ | 4,428 | $ | 3,006 | ||||
| Capital expenditures incurred but not yet paid | $ | 49 | $ | 40 | ||||
The following table summarizes revenue by product line for the three and nine months ended
| Three Months Ended | Nine Months Ended | |||||||||||||||
| (In thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenue | ||||||||||||||||
| Lymphedema products | $ | 65,282 | $ | 62,506 | $ | 182,278 | $ | 172,257 | ||||||||
| Airway clearance products | 7,811 | 7,080 | 25,121 | 24,514 | ||||||||||||
| Total | $ | 73,093 | $ | 69,586 | $ | 207,399 | $ | 196,771 | ||||||||
| Percentage of total revenue | ||||||||||||||||
| Lymphedema products | 89 | % | 90 | % | 88 | % | 88 | % | ||||||||
| Airway clearance products | 11 | % | 10 | % | 12 | % | 12 | % | ||||||||
| Total | 100 | % | 100 | % | 100 | % | 100 | % | ||||||||
The following table contains a reconciliation of GAAP gross profit and margin to non-GAAP gross profit and margin:
| Reconciliation of Gross Profit and Margin to Non-GAAP Gross Profit and Margin | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| (Dollars in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Gross profit, as reported | $ | 54,787 | $ | 49,359 | $ | 152,319 | $ | 139,126 | ||||||||
| Gross margin, as reported | 75.0 | % | 70.9 | % | 73.4 | % | 70.7 | % | ||||||||
| Reconciling items: | ||||||||||||||||
| Non-cash intangible asset amortization expense | $ | 317 | $ | 316 | $ | 950 | $ | 945 | ||||||||
| Non-GAAP gross profit | $ | 55,104 | $ | 49,675 | $ | 153,269 | $ | 140,071 | ||||||||
| Non-GAAP gross margin | 75.4 | % | 71.4 | % | 73.9 | % | 71.2 | % | ||||||||
The following table contains a reconciliation of GAAP operating income to non-GAAP operating income:
| Reconciliation of GAAP Operating Income to Non-GAAP Operating Income | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| (Dollars in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| GAAP operating income | $ | 6,781 | $ | 7,989 | $ | 9,666 | $ | 6,241 | ||||||||
| Reconciling items: | ||||||||||||||||
| Non-cash intangible asset amortization expense impacting gross profit | $ | 317 | $ | 316 | $ | 950 | $ | 945 | ||||||||
| Non-cash intangible asset amortization expense impacting operating expenses | 633 | 633 | 1,898 | 1,919 | ||||||||||||
| Change in fair value of earn-out | — | (3,705 | ) | — | (2,475 | ) | ||||||||||
| Executive transition expenses | 136 | — | 111 | — | ||||||||||||
| Non-GAAP operating income: | $ | 7,867 | $ | 5,233 | $ | 12,625 | $ | 6,630 | ||||||||
The following table contains a reconciliation of GAAP net income to non-GAAP net income:
| Reconciliation of GAAP Net Income to Non-GAAP Net Income | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| (Dollars in thousands) | 2024 | 2023 | 2024 | 2023 | ||||||||||||
| GAAP net income | $ | 5,155 | $ | 22,299 | $ | 7,244 | $ | 20,313 | ||||||||
| Reconciling items: | ||||||||||||||||
| Non-cash intangible asset amortization expense impacting gross profit | $ | 317 | $ | 316 | $ | 950 | $ | 945 | ||||||||
| Non-cash intangible asset amortization expense impacting operating expenses | 633 | 633 | 1,898 | 1,919 | ||||||||||||
| Change in fair value of earn-out | — | (3,705 | ) | — | (2,475 | ) | ||||||||||
| Executive transition expenses | 136 | — | 111 | — | ||||||||||||
| Income tax expense on reconciling items* | (272 | ) | 689 | (740 | ) | (97 | ) | |||||||||
| Non-GAAP net income | $ | 5,969 | $ | 20,232 | $ | 9,463 | $ | 20,605 | ||||||||
| * The effect of income tax on the reconciling items is estimated using the Company's effective statutory tax rate. | ||||||||||||||||
The following table contains a reconciliation of net income to Adjusted EBITDA for the three and nine months ended
| Reconciliation of Net Income to Non-GAAP Adjusted EBITDA | ||||||||||||||||||||||||||||||||
| (Unaudited) | ||||||||||||||||||||||||||||||||
| Three Months Ended | Increase | Nine Months Ended | Increase | |||||||||||||||||||||||||||||
| (Decrease) | (Decrease) | |||||||||||||||||||||||||||||||
| (Dollars in thousands) | 2024 | 2023 | $ | % | 2024 | 2023 | $ | % | ||||||||||||||||||||||||
| Net income | $ | 5,155 | $ | 22,299 | $ | (17,144 | ) | (77 | ) | % | $ | 7,244 | $ | 20,313 | $ | (13,069 | ) | 64 | % | |||||||||||||
| Interest (income) expense, net | (452 | ) | 404 | (856 | ) | N.M. | % | (823 | ) | 2,235 | (3,058 | ) | (137 | ) | % | |||||||||||||||||
| Income tax expense (benefit) | 2,078 | (14,714 | ) | 16,792 | (114 | ) | % | 3,254 | (16,307 | ) | 19,561 | (120 | ) | |||||||||||||||||||
| Depreciation and amortization | 1,734 | 1,646 | 88 | 5 | % | 5,079 | 4,915 | 164 | 3 | % | ||||||||||||||||||||||
| Stock-based compensation | 2,070 | 1,766 | 304 | 17 | % | 5,969 | 5,597 | 372 | 7 | % | ||||||||||||||||||||||
| Change in fair value of earn-out | — | (3,705 | ) | 3,705 | (100 | ) | % | — | (2,475 | ) | 2,475 | (100 | ) | % | ||||||||||||||||||
| Executive transition costs | 136 | — | 136 | — | % | 111 | — | 111 | — | % | ||||||||||||||||||||||
| Adjusted EBITDA | $ | 10,721 | $ | 7,696 | $ | 3,025 | 39 | % | $ | 20,834 | $ | 14,278 | $ | 6,556 | 46 | % | ||||||||||||||||
Investor Inquiries:
[email protected]
Source: Tactile Systems Technology, Inc.